Vitamin K2 May Influence Neuromuscular Signaling: RCT

Why It Matters

If confirmed, K2 could become a targeted micronutrient for preserving neuromuscular function in older adults, a market with growing demand for age‑related performance solutions.

Key Takeaways

• Vitamin K2 MK‑7 showed no overall recovery benefit in all participants.
• In adults 65+, supplementation shortened electromechanical delay after resistance exercise.
• IL‑6 and creatine kinase showed age‑specific interaction but inconsistent over time.
• Study lacked middle‑aged participants, limiting broader interpretation of results.
• Findings suggest K2 may influence neuromuscular signaling, supporting healthy aging.

Pulse Analysis

Vitamin K2, traditionally valued for bone health and cardiovascular support, is now being explored for its role in muscle function. The TAKEOVER trial, a double‑blind, 12‑week RCT, administered 180 µg of MK‑7 daily to two age groups and measured classic recovery outcomes—strength, soreness, and inflammatory markers. While the supplement failed to move these conventional metrics in the combined cohort, the study’s design provides a rigorous baseline for future investigations into less‑obvious pathways such as neural‑muscle communication.

The most intriguing signal emerged from participants 65 years and older, where vitamin K2 shortened electromechanical delay (EMD), the latency between neural activation and muscle contraction. A reduced EMD can translate to quicker force production, a critical factor for fall prevention and functional independence in seniors. Concurrent, albeit inconsistent, changes in interleukin‑6 and creatine‑kinase suggest that K2 may modulate inflammatory cascades and muscle membrane integrity via vitamin‑K‑dependent proteins like Gas6, which interact with TAM receptors in motor neurons. These mechanistic hints align with emerging pre‑clinical data linking K2 to neuro‑muscular health.

For the supplement industry, the findings open a niche beyond “maintenance” claims, positioning K2 as a performance‑relevant nutrient for the aging demographic—a segment projected to exceed $300 billion in U.S. health‑spending by 2030. However, the study’s omission of the 40‑65 age bracket and the variability of biomarker responses underscore the need for broader, longer‑term trials. Should subsequent research replicate the neuromuscular benefits, we could see K2 fortified in protein powders, recovery drinks, and targeted geriatric formulations, reshaping how clinicians and athletes approach micronutrient‑driven performance longevity.